- Home
- NTRB vs MGX Comparison
NTRB vs MGX Comparison
Compare NTRB & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- MGX
- Stock Information
- Founded
- NTRB 2016
- MGX 2018
- Country
- NTRB United States
- MGX United States
- Employees
- NTRB N/A
- MGX N/A
- Industry
- NTRB Industrial Specialties
- MGX
- Sector
- NTRB Health Care
- MGX
- Exchange
- NTRB Nasdaq
- MGX NYSE
- Market Cap
- NTRB 77.9M
- MGX 70.4M
- IPO Year
- NTRB N/A
- MGX 2024
- Fundamental
- Price
- NTRB $4.73
- MGX $1.82
- Analyst Decision
- NTRB
- MGX Strong Buy
- Analyst Count
- NTRB 0
- MGX 7
- Target Price
- NTRB N/A
- MGX $15.50
- AVG Volume (30 Days)
- NTRB 18.3K
- MGX 378.5K
- Earning Date
- NTRB 12-11-2024
- MGX 11-13-2024
- Dividend Yield
- NTRB N/A
- MGX N/A
- EPS Growth
- NTRB N/A
- MGX N/A
- EPS
- NTRB N/A
- MGX N/A
- Revenue
- NTRB $1,803,816.00
- MGX $55,080,000.00
- Revenue This Year
- NTRB N/A
- MGX $0.39
- Revenue Next Year
- NTRB N/A
- MGX N/A
- P/E Ratio
- NTRB N/A
- MGX N/A
- Revenue Growth
- NTRB N/A
- MGX 45.13
- 52 Week Low
- NTRB $2.09
- MGX $1.81
- 52 Week High
- NTRB $9.60
- MGX $12.74
- Technical
- Relative Strength Index (RSI)
- NTRB 35.59
- MGX 36.82
- Support Level
- NTRB $4.63
- MGX $1.96
- Resistance Level
- NTRB $5.33
- MGX $2.30
- Average True Range (ATR)
- NTRB 0.39
- MGX 0.20
- MACD
- NTRB -0.13
- MGX -0.00
- Stochastic Oscillator
- NTRB 5.65
- MGX 1.89
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).